$114.77
▲ +$0.02
(+0.02%)
Vol 1.2M
2
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$3.8B
ROE
-51.1%
Margin
-607.3%
D/E
0.00
Beta
0.33
52W
$48–$94
Wall Street Consensus
23 analysts · Apr 20260
Strong Buy
0
Buy
20
Hold
1
Sell
2
Strong Sell
0.0%
Buy Rating
Price Chart
Similar Stocks
HALO
Halozyme Therapeutics Inc
P/E 13.3
$7.9B
IBRX
Immunitybio Inc
$2.0B
KYMR
Kymera Therapeutics Inc
$6.1B
PTGX
Protagonist Therapeutics Inc
P/E 118.9
$5.5B
RYTM
Rhythm Pharmaceuticals Inc
$7.1B
SRRK
Scholar Rock Holding Corp
$4.5B
COGT
Cogent Biosciences Inc
$5.4B
CGON
CG Oncology Inc
$3.3B
MIRM
Mirum Pharmaceuticals Inc
$4.1B
Earnings
Beat rate: 75.0%
Next Report
May 06, 2026
EPS Estimate: $-1.14
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-1.14 | — | — |
| Dec 2025 | $-1.06 | $-1.01 | +$0.05 |
| Sep 2025 | $-1.08 | $-0.99 | +$0.09 |
| Jun 2025 | $-1.04 | $-0.94 | +$0.10 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -43.0% | -43.0% | -43.0% | -43.0% | -51.1% | -51.1% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -701.6% | -329.9% | -329.9% | -329.9% | -607.0% | -607.3% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 3.80 | 3.81 | 3.81 | 3.81 | 3.99 | 4.00 |
Key Ratios
ROA (TTM)
-33.1%
P/S (TTM)
105.02
P/B
9.1
EPS (TTM)
$-3.93
CF/Share
$-2.73
52W High
$94.07
52W Low
$47.86
$47.86
52-Week Range
$94.07
How does ACLX compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
ACLX valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
105.0
▲
717%
above
peers
(12.9)
vs Peers
vs Industry
Pricier
P/B ratio
9.1
▲
271%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
ACLX profitability vs Biotechnology peers
ROE
-51.1%
▲
24%
above
peers
(-67.3%)
vs Peers
vs Industry
Below avg
Net margin
-607.3%
▼
112%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-33.1%
▲
29%
above
peers
(-46.7%)
vs Peers
vs Industry
Below avg
ACLX financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
4.0
▼
10%
below
peers
(4.4)
vs Peers
vs Industry
In line
Beta
0.3
▼
66%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
ACLX fundamentals radar
ACLX
Peer median
Industry
ACLX profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio